Trade

with

Lexicon Pharmaceuticals Inc
(NASDAQ: LXRX)
AdChoices
1.40
+0.03
+2.19%
After Hours :
1.40
0.00
0.00%

Open

1.38

Previous Close

1.37

Volume (Avg)

642.95k (856.18k)

Day's Range

1.35-1.40

52Wk Range

1.04-2.57

Market Cap.

720.75M

Dividend Rate ( Yield )

-

Beta

2.04

Shares Outstanding

514.82M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 2.22M

    • Net Income

    • -104.13M

    • Market Cap.

    • 720.75M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -4,072.86

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.04

    • Forward P/E

    • -7.78

    • Price/Sales

    • 277.78

    • Price/Book Value

    • 6.18

    • Price/Cash flow

    • -7.25

      • EBITDA

      • -99.29M

      • Return on Capital %

      • -38.70

      • Return on Equity %

      • -63.86

      • Return on Assets %

      • -38.70

      • Book Value/Share

      • 0.23

      • Shares Outstanding

      • 514.82M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 4.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.18

        • Cashflow Estimate

        • -0.14

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 215.90

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -41.46

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -4,072.86

            • 39.38

            • Net Profit Margin

            • -4,072.86

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -4,807.80

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -4,787.80

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.17

              • 0.76

              • Current Ratio

              • 3.96

              • 2.92

              • Quick Ratio

              • 3.62

              • 2.35

              • Interest Coverage

              • -55.32

              • 38.02

              • Leverage Ratio

              • 1.92

              • 2.21

              • Book Value/Share

              • 0.23

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -6.55

                • 217.39

                • P/E Ratio 5-Year High

                • -15.91

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.93

                • 124.82

                • Price/Sales Ratio

                • 270.27

                • 9.52

                • Price/Book Value

                • 5.96

                • 8.61

                • Price/Cash Flow Ratio

                • -7.25

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -63.86

                        (-45.30)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -38.70

                        (-30.70)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -55.43

                        (-38.10)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.01

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -102.37M
                      Operating Margin
                      -4,607.16
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -7.25
                      Ownership

                      Institutional Ownership

                      89.13%

                      Top 10 Institutions

                      82.44%

                      Mutual Fund Ownership

                      25.09%

                      Float

                      29.84%

                      5% / Insider Ownership

                      0.43%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Growth Company Fund

                      •  

                        38,430,427

                      • 0.11

                      • 7.46

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        10,295,323

                      • 0.00

                      • 2.00

                      • Fidelity® Series Growth Company Fund

                      •  

                        9,261,015

                      • 0.11

                      • 1.80

                      • Fidelity Advisor® Growth Opportunities

                      •  

                        8,418,904

                      • 0.00

                      • 1.64

                      • iShares Nasdaq Biotechnology

                      •  

                        6,660,468

                      • -0.47

                      • 1.26

                      • T. Rowe Price Small Cap Value Fund

                      •  

                        5,554,100

                      • -0.37

                      • 1.08

                      • Vanguard Small Cap Index

                      •  

                        4,041,241

                      • 0.08

                      • 0.78

                      • Vanguard Total Stock Mkt Idx

                      •  

                        3,883,695

                      • 0.00

                      • 0.75

                      • iShares Russell 2000 (AU)

                      •  

                        3,392,951

                      • -1.46

                      • 0.64

                      • Vanguard Extended Market Index Fund

                      •  

                        2,945,250

                      • 0.67

                      • 0.57

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Artal Group S A

                      •  

                        253,372,135

                      • 0.00%

                      • 49.23

                      • Fidelity Management and Research Company

                      •  

                        77,241,324

                      • +0.22%

                      • 15.01

                      • Ulys, LLC

                      •  

                        29,782,609

                      • 0.00%

                      • 5.79

                      • Vanguard Group, Inc.

                      •  

                        14,615,987

                      • +4.69%

                      • 2.84

                      • NEA Management Company, LLC

                      •  

                        11,676,000

                      • 0.00%

                      • 2.27

                      • UBS Global Asset Mgmt Americas Inc

                      •  

                        11,552,278

                      • +4.23%

                      • 2.24

                      • BlackRock Fund Advisors

                      •  

                        11,123,645

                      • -7.91%

                      • 2.16

                      • T. Rowe Price Associates, Inc.

                      •  

                        6,124,090

                      • -5.12%

                      • 1.19

                      • UBS Global Asset Management Zurich

                      •  

                        5,206,533

                      • +0.94%

                      • 1.01

                      • State Street Corp

                      •  

                        3,590,526

                      • -52.85%

                      • 0.70

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Slow Growth

                      Style

                      Small Growth

                      Lexicon Pharmaceuticals Inc was incorporated in Delaware on July 7, 1995. The Company operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. It has used its propriet...moreary gene knockout technology and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. It has identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery. The Company has also advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and resea...morerch and believe that its systematic, target biology-driven approach to drug discovery will enable it to continue to expand its clinical pipeline. It faces significant competition in each of the aspects of its business from other pharmaceutical and biotechnology companies. The development, manufacture and sale of any drug or biologic products developed by the Company or its collaborators will be subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.lessless

                      Key People

                      Mr. Lonnel Coats

                      CEO/Director/President

                      Mr. Raymond Debbane

                      Chairman of the Board/Director

                      Dr. Brian P. Zambrowicz,PhD

                      Co-Founder/Chief Scientific Officer/Executive VP

                      Jeffrey L. Wade

                      CFO/Executive VP, Divisional

                      Dr. Alan J. Main,PhD

                      Executive VP, Divisional

                      • Lexicon Pharmaceuticals Inc

                      • 8800 Technology Forest Place

                      • The Woodlands, TX 77381

                      • USA.Map

                      • Phone: +1 281 863-3000

                      • Fax: +1 281 863-8088

                      • lexicon-genetics.com

                      Incorporated

                      1995

                      Employees

                      149

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: